From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
OnDemand
As the 340B program passes the 30-year mark, seminal events in the program’s history have shaped the landscape we see today. Far from being a bureaucratic regulation that all parties sleepily adopt, the 340B program has become a hot button for all those involved as well as those seeking to impact it from beyond the typical Covered Entity, Manufacturer, and Government participants. With so many dollars at stake, attention –and tension– is riding high on actions by the existing stakeholders that have made a significant impact on the program in ways that were unimaginable a few short years ago.
Watch Tim Paine, Principal Consultant at Blue Fin Group, an IntegriChain Company as he discusses these changes and their impact on patients, payers, and manufacturers and estimates where the 340B program will be in the next 10 years.
Tim PainePrincipal ConsultantBlue Fin Group, An IntegriChain Company
